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Case-based surveyAbstract Introduction: Synchronous oligometastatic non-small cell lung cancer (NSCLC)
definition varies from 1 metastasis in 1 organ (tumour-node-metastasis 8 [TNM8]), 1e3 me-
tastases (European Society for Medical Oncology [ESMO]), 3 metastases (including medias-
tinal nodes [MLN]) after systemic treatment to 3e5 metastases in ongoing trials. A single
definition is however needed to design/compare trials. To assess oligometastatic NSCLC def-
initions used by clinical experts in daily practice and its evolution, we redistributed a 2012
case-based survey (Dooms, the World Congress of Lung Cancer 2013).
Methods: In December 2017, 10 real-life multidisciplinary team (MDT) discussed patients
(good condition, no significant comorbidities, 18F-fluorodeoxyglucose positron emission to-
mography/brain magnetic resonance imaging staged, all < 5 metastases, 9/10  3 metastases,
oncogene-addicted or wild-type) were distributed to 33 international NSCLC experts involved
in the European Organisation for Research and Treatment of Cancer oligometastatic NSCLC
consensus group, questioning is this oligometastatic disease and if oligometastatic, which
treatment proposal. The answers provided in 2017 were compared with the 2012 answers;
real-life treatment and survival of the patients was added.
Results: Twenty-six of 33 experts (24 centres) replied: 8 medical oncologists, 7 pulmonologists,
7 radiation oncologists, 4 thoracic surgeons. Sixty-two percent of respondents discussed the
cases with their MDT. One case had 100% oligometastatic consensus, and 3 cases had
>90% consensus; the number of treatment proposals varied between 3 and 8. Radical treat-
ment was more often offered in case of single metastasis or N0. Compared with 2012, there
was a trend towards a more conservative oligometastatic definition and chemotherapy was
more frequently included in the treatment proposal.
Conclusions: Oligometastatic NSCLC definition was conservative. The number of organs,
MLN status and radical treatment possibility seem to be components of daily practice oligo-
metastatic definition.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Patients with metastasised non-small cell lung cancer
(NSCLC) are generally considered incurable. However,
it is suggested that some patients have an intermediate
state, between localised disease and widespread metas-
tases, and that they could benefit from more aggressive
treatment. The term ‘oligometastases’ has first been
proposed in 1995 by Hellman et al. [1], describing a
clinically significant state with a limited number of me-
tastases in a single or a limited number of organs. They
also suggested that oligometastatic patients can be
treated with local radical therapy (LRT) with radical
intent but that further studies are needed to identify
patients who will benefit the most [1]. Synchronous
oligometastases is defined as a diagnosis of oligometa-
stases at the first diagnosis of metastatic NSCLC.
Several, mainly retrospective series showed that a
subset of these radically treated patients can indeed
obtain a long-term survival, especially those with a
single brain or adrenal metastasis and N0 disease
[2e8]. The first prospective trial (single arm, phase II)
was published in 2012 [9]. Eligible patients were those
with stage IV NSCLC with less than five synchronous
metastases, amenable for LRT. Eighty-seven percent
of the included patients had a single metastasis, and
95% of them received chemotherapy as part of theirprimary treatment. Two- and three-year survival rates
were 23.3% and 17.5%, respectively [9]. With the
published series and the widespread introduction of
minimal invasive surgery and stereotactic radio-
therapy, the concept of delivering LRT in patients
with oligometastatic NSCLC gained increasing inter-
est and was also incorporated in NSCLC guidelines.
For example, the European Society for Medical
Oncology guideline states that definition for oligo-
metastatic disease varies but that patients with one to
three synchronous metastases can be treated with
radical intent, preferably in a clinical trial [10]. The
National Comprehensive Cancer Network guideline
states that patients with NSCLC with limited metas-
tases can receive LRT [11]. The 8th TNM classifica-
tion of lung cancer also included the concept: M1b
defines a single metastasis in a single site, and M1b
patients were shown to have a superior prognosis than
M1c patients, although treatment was not known for
these patients [12]. After the first prospective phase II
trial, three other trials including patients with syn-
chronous oligometastatic NSCLC have been reported
with promising progression-free survival (PFS) data
[13e15]. Only for one trial, overall survival (OS) re-
sults have been reported, with a median OS of 41.2
months for the LRT arm and 17 months for the con-
trol arm [15]. The inclusion criteria such as the
Table 1
Summary of completed and reported oligometastatic trials in non-small cell lung cancer.
Author, year,
phase trial
Nr of patients
with NSCLC
included
Max nr of
metastatic sites
Max nr of
organs with
metastases
Primary/
LN
counted
Treatment Outcome Characteristics
included
patients
De Ruysscher
(update 2018),
II single arm
40
All histologies
5 5 No LRT  chemotx OS at 2 years: 23.3%
OS at 3 years: 17.5%
OS at 5 years: 7.7%
OS at 6 years: 2.5%
87% single met
41.1% N0-1
Gomez (update
2019), II
randomised
49
All histologies
Counted after
first-line
systemic tx: 3
3 Yes
(MLN)
A:
LRT þ maintenance
B: maintenance
Median PFS 11.9 (LRT)
versus 3.9 months (HR 0.35;
p Z 0.0054)
median OS 41.2 (LRT)
versus 17 months<
68% 0e1 non-
regional mets
48% N0-1
Iyengar
2017, II
randomised
29
Non-EGFR/
ALK
6 including
primary
Max 3 in liver/
lung
5 Yes Chemotx followed by
A:
LAT þ maintenance
chemo
B: maintenance chemo
Median PFS 9.7 (LRT)
versus 3.5 months (HR 0.30;
p Z 0.01)
Median sites of
disease: 3
MLN not
mentioned
Bauml
2018, II single
arma
45
All histologies
4 4 No LRT to all sites
followed by
pembrolizumab
12-month PFS 728%
18-month PFS 54%
24-month PFS 50%
63.6% single
met
61.4% N0-1
Abbreviations: NSCLC: non-small cell lung cancer; max: maximum; nr: number; MLN: mediastinal lymph nodes; LRT: local radical therapy; OS:
overall survival; mets: metastases: tx: therapy; PFS: progression-free survival; vs: versus; HR: hazard ratio; EGFR: epidermal growth factor re-
ceptor; ALK: anaplastic lymphoma kinase; chemo: chemotherapy.
a No limits on prior lines of therapy, but patient should be programmed death-(ligand)1 inhibitor naive.
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mediastinal lymph nodes, eligibility of patients with
driver mutations and treatment sequence varied
(Table 1) [16].
As it is clear from these summarised trials and
guidelines, definition of synchronous oligometastatic
NSCLC varies. Furthermore, even though most trials
allow at least three metastatic sites and do not restrict on
mediastinal lymph nodes, most enrolled patients have
only one metastatic site and N0-1 disease (Table 1)
[13e15]. A single oligometastatic definition is, however,
needed to design and compare trials. The European
Organisation for Research and Treatment of Cancer
Lung Cancer Group (EORTC-LCG) initiated a
consensus process. A consensus group was formed
aiming to agree on a common NSCLC synchronous
oligometastatic definition that could be used in future
clinical trials. In preparation for this meeting, a sys-
tematic review [17] and a survey [18] were performed.
Furthermore, we redistributed a 2012 case-based survey
(Dooms et al.[19], presented at the World Congress of
Lung Cancer 2013) to a larger expert panel. This is to
assess synchronous oligometastatic NSCLC definitions
used by clinical experts in daily practice and its evolu-
tion. Results of this case-based survey are reported here.2. Materials and methods
2.1. Cases
The original 2012 case-based survey was developed in
preparation for a workshop on oligometastatic NSCLCin Leuven, Belgium, and consisted of ten real-life
multidisciplinary team (MDT) discussed patients.
These patients were in a good clinical condition, had no
significant comorbidities and were all 18F-fluorodeox-
yglucose positron emission tomography (18FFDG-PET)
and brain magnetic resonance imaging (MRI) staged.
All patients had less than five metastases, and nine of
them had three or less metastases. Both oncogene-
addicted (epidermal growth factor receptor [EGFR]e
mutated) and wild-type NSCLC cases were included.
The 7th TNM edition was initially used for these cases
but was recoded to the 8th edition for this analysis
[20,21]. The cases can be found in the supplementary
material (appendix 1). These patients were diagnosed
with stage IV NSCLC between 2009 and 2012; the last
date of follow-up was January 5, 2018.2.2. Distribution of cases
In 2012, this survey was sent to 11 experts in the field
with the following questions: (1) Is this oligometastatic
disease? And (2) Can you state what your preferred
treatment is?
In December 2017, the same cases were distributed to
33 international NSCLC experts involved in the Euro-
pean Organisation for Research and Treatment of
Cancer (EORTC) oligometastatic NSCLC consensus
group (including four young investigators), with the
following questions: (1) What is your working environ-
ment? (2) Can you please discuss these cases in your
MDT? (3) Do these patients have oligometastatic dis-
ease? And (4) What is your treatment proposal for each
Table 2
Summary of clinical cases and expert answers.
Case TNM8 OMD
agreement
(% positive
answer)
2012/2017
Number of tx
proposalsa
2012/2017
% of
treatment
proposals
including
systemic txa
2012/2017
% of
radical
tx
answersa
2012/
2017
Real-
life
radical
tx
intent
Real life tx Real-life survival
(mo)
alive at 5 yrs (þ:
yes, -:
no)/with or
without
active disease
(1) EGFR þ cT2aN3M1c (3
brain mets)
55/38 3/5 100/100 50/60 No EGFR-TKI 40.1-/NA
(2) EGFR þ cT4N0M1a
(ground glass)
36/35 4/3 60/78 100/100 Yes VATS lobectomy
RUL þ wedge ML,
adjuvant chemotx 2016 PD:
EGFR-TKI
65.2þ/with
(3) cT2bN1M1b (solitary
renal)
91/96 5/5 80/91 100/96 Yes cCRT chest and partial
nephrectomy
8.3-/NA
(4) cT1cN3M1b (solitary
adrenal)
73/58 4/5 100/100 75/93 Yes Induction chemotx,
radical RT chest,
adrenalectomy
66.1þ/without
(5) cT3N1M1c
(adrenal þ pelvic node)
55/50 3/5 100/92 67/92 No Chemotx 18.6-/NA
(6) cT2aN0M1c
(3 liver mets)
64/69 4/5 71/83 43/89 No Chemotx 51.5-/NA
(7) cT2aN2M1b (solitary
bone)
91/92 4/5 80/100 80/92 Yes Induction chemotx,
lobectomy RLL, adjuvant
chest RT, scapula RT
13.4-/NA
(8) cT2bN1M1c (2 brain
mets)
91/96 3/8 100/84 80/88 Yes SRT brain, cCRT chest 39.6-/NA
(9) cT2bN0M1c (1 lung, 1
pancreas)
82/69 6/4 78/94 78/72 Yes VATS lobectomy LUL, SRT
pancreas,
adjuvant chemotx
74.0þ/without
(10) cT1bN0M1b (solitary
bone)
100/100 3/5 9/54 91/92 Yes VATS lobectomy RUL, SRT
C6,
adjuvant chemotx
11.6-/NA
Abbreviations: TNM: tumour-node-metastasis; OMD: oligometastatic disease; tx: treatment; mo: months; yrs: years; EGFR: epidermal growth
factor receptor; mets: metastases; TKI: tyrosine kinase inhibitor; VATS: video-assisted thoracoscopic surgery; RUL: right upper lobe; ML: middle
lobe; PD: progressive disease; cCRT: concurrent chemoradiotherapy; RT: radiotherapy; RLL: right lower lobe; SRT: stereotactic radiotherapy;
NA: not applicable.
a Only results given for respondents who answered that the case was oligometastatic.
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remarks or comments regarding the way their decision
was made. The responders were not aware of the actual
treatment of the cases and did not know the 2012 an-
swers. Current results were compared with the 2012
answers, and the real-life applied treatment and survival
data of the patients were added (the last date of follow-
up was January 5, 2018).
2.3. Statistics
Statistical analysis was performed with Excel 2016.
Descriptive statistics were used to describe all answers to
the cases, and the Fisher exact test was used to evaluate
if the answer in 2017 (oligometastatic yes/no) was
related to whether a case was discussed in the MDT.3. Results
2012 and 2017 results plus real-life outcomes are sum-
marised in Table 2. Detailed treatment answers (type ofLRT, type of systemic treatment, sequence of treatment
[if mentioned in the answer]) can be found in
Supplemental Table 1.3.1. 2012
In 2012, 11 experts (three radiation oncologists, three
thoracic surgeons, three pulmonologists, one pathol-
ogist and one specialist in nuclear medicine) answered
all ten cases. The answers are summarised in Table 1.
Only one case (case 10) had 100% consensus that this
was oligometastatic disease. For the other cases,
agreement ranged from 36 to 91%. The number of
treatment options per oligometastatic case ranged
from two to six. The percentage of responders that
included systemic treatment in their treatment pro-
posal for the cases they considered oligometastatic
ranged from 9 to 100%. The lowest percentage of
systemic treatment use was found for the 100% oli-
gometastatic consensus case 10 (cT1bN0M1b). Even
though responders considered a case oligometastatic,
L.E.L. Hendriks et al. / European Journal of Cancer 123 (2019) 28e3532the percentage of treatment with radical intent (i.e.
LRT given to all disease sites) for oligometastatic
cases varied from 43 to 100%. The lowest percentage
was found for case 6.3.2. 2017 and comparison with 2012
In 2017, 26 of 33 (78.8%) experts from 24 different in-
stitutions (11 countries) responded and answered all
cases. Six worked in a cancer centre, 19 in a university
centre and one in a general hospital. One was a clinical
oncologist, seven were medical oncologists, seven pul-
monologists, seven radiation oncologists and four
thoracic surgeons. Sixteen of them (62%) discussed all
cases in their local MDT.
In general, remarks were made that in case of a sol-
itary metastasis, pathology proof should be obtained
when feasible. One respondent stated that mediastino-
scopy was necessary in patients with N0/1 disease when
mediastinoscopy was not already performed. When a
case was not considered oligometastatic, reasons were
the extent of locoregional disease, the number of me-
tastases or their location (i.e. LRT not possible).
For the same patient case (number ten) as in 2012,
there was 100% consensus in 2017 that this was oligo-
metastatic disease. For the other cases, agreement
ranged from 38 to 96%. The four cases with an agree-
ment of more than 90% were cases with N0 or N1 dis-
ease (and one N2 case with a solitary micrometastasis in
lymph node station 4R) and a single metastasis (one case
with 2 brain metastases). There was no association be-
tween the decision that a case was oligometastatic and
discussing the case in the MDT except for case 5. In case
5, 45% of those presenting the case in the MDT stated
that it was oligometastatic disease while 80% not dis-
cussing in the MDT stated it was oligometastatic disease
(p Z 0.04).
For seven cases, the percentage of oligometastatic
agreement did not differ for more than 5% when 2012
and 2017 answers were compared. For the other three
cases, the percentage of oligometastatic agreement was
13e17% lower in 2017 than in 2012. In 2017, the
number of treatment options ranged from three to
eight, and for seven cases, this number was higher in
2017 than in 2012. The percentage of responders that
included systemic treatment in 2017 was 54e100%.
Systemic treatment was proposed as neoadjuvant,
concurrent and adjuvant approaches (Supplemental
Table 1). For two cases, the use of systemic treat-
ment percentage was more than 5% lower than in 2012
(8% and 16%, respectively); for six, it was more than
5% higher (range, 11e45%). In 2017, the percentage of
treatment with radical intent for the oligometastatic
cases ranged from 60 to 100%, was 5% lower than in
2012 in one case and more than 5% higher in six cases
(range 10e46%).3.3. Real-life outcomes
In real life, seven patients were treated with radical
intent (Table 2). Two of them were treated with induc-
tion chemotherapy followed by LRT, and the others
were treated with LRT and concurrent or adjuvant
systemic treatment. Three of these seven patients were
alive at five years, and none of the non-radically treated
patients were alive at five years. Patient six was treated
with palliative chemotherapy only and died after 51.5
months of a second primary metastatic chol-
angiocarcinoma. In hindsight, it was possible that the
liver lesions were metastases of a cholangiocarcinoma
although median OS of a non-radically treated chol-
angiocarcinoma is less than one year [22] Patient ten,
with 100% oligometastatic consensus received radical
treatment but died after 11.6 months (Table 1).4. Discussion
With the introduction of minimally invasive LRT tech-
niques and the superior survival outcomes with LRT
added to systemic treatment [13,15,23], there is increased
interest in radically treating (synchronous) patients with
oligometastatic NSCLC. However, definition for syn-
chronous oligometastatic NSCLC varies across guide-
lines and trials where only selected patients are included.
Furthermore, more oligometastatic patients are treated
with LRT in daily practice, and it is not known whether
this type of oligometastatic patients treated mirrors that
of the clinical trials.
We showed that the oligometastatic definition in
daily clinical practice was conservative: even though all
cases had less than five metastases and 90% had three or
less metastases, only one case had 100% consensus that
this was oligometastatic disease. Three other cases had
more than 90% oligometastatic consensus: two of these
cases had a solitary metastasis, the other had two brain
metastases and all cases had N0 (or micrometastatic N)
disease. The oligometastatic definition was more
restrictive in 2017 than in 2012, but cases with the
highest agreement on oligometastatic disease remained
the same. The number of metastatic sites, mediastinal
lymph node status and possibility for LRT seem to be
components that are taken into account by experts for
oligometastatic definition and treatment in daily
practice.
Interestingly, there seems to be a discrepancy between
a theoretical definition of oligometastatic disease (i.e.
not linked to a specific patient case) and the practical
definition of oligometastatic disease. This is shown for
clinical trials as well as daily practice. Despite that most
trials allow up to three or five metastatic sites (some
even more) and do not restrict on the presence of
mediastinal lymph node metastases, most enrolled pa-
tients have only one metastatic lesion and N0 or N1
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practice as demonstrated in a European survey on syn-
chronous oligometastatic NSCLC definition that we
performed at the end of 2017 e beginning of 2018 (444
responders). Forty-two percent included up to three
metastases in their definition, 16% included up to five
metastases and 16% had no upper limit, if LRT was
possible. Only 25% stated that mediastinal lymph node
involvement was not allowed to be classified as oligo-
metastatic NSCLC [18]. Despite these relatively broad
inclusion criteria for oligometastatic disease, our cases
showed that mainly the patients with a single metastasis
and N0-1 disease were considered oligometastatic and
were treated with LRT. However, to be able to design
and compare trials, a single definition is needed. The
EORTC oligometastatic definition group has formu-
lated a consensus statement on the definition of syn-
chronous oligometastatic NSCLC [16]. This definition
should be prospectively tested in future randomised
trials and in the EORTC-ESTRO (European Society for
Therapeutic Radiation and Oncology) OligoCare proj-
ect (a pragmatic observational basket study to evaluate
radical radiotherapy for oligometastatic cancer pa-
tients). As such, this definition might change with
continuing new insights. Another factor that is impor-
tant for the definition is the required staging for these
patients. This was not addressed in this survey as all
patients were 18FFDG-PET and brain MRI staged as
proposed by the EORTC imaging group [25]. However,
staging requirements vary in ongoing trials.
Another finding from this survey is the number of
treatment options per oligometastatic case. For most
cases, four to five different treatment scenarios were
mentioned, and up to eight in one case. Treatment op-
tions varied with respect to the LRT technique (surgery,
S(B)RT and radiofrequency ablation) and also for sys-
temic treatment (type and sequence [induction, concur-
rent and adjuvant]). However, the therapeutic sequence
seems important for oligometastatic disease, as usually
only the patients who do not progress with induction
systemic treatment are selected for LRT (cf Gomez and
Iyengar trials) [13,15,23]. Maybe some of the patient
cases in this survey would not have been treated with
LRT when systemic treatment had been given upfront.
The trial by Iyengar et al [13] was published just after
the completion of our case-based survey, and it is
possible that more experts would have selected upfront
systemic treatment followed by LRT if this article had
been published before the distribution of the cases.
However, even though sensitivity to systemic treatment
can enrich the oligometastatic patient population for
long-term benefit, treatment sequence (sequential versus
concurrent) was not associated with the outcome in
another trial [9,26]. Moreover, in the updated analysis of
this trial, with a minimal follow-up of more than seven
years, five- and six-year survival rates were only 7.7%
and 2.5%, respectively [26].Better selection methods are needed to identify oli-
gometastatic patients who will benefit from LRT in
addition to systemic treatment. The number and
sometimes also location of metastasis, volume of dis-
ease and nodal status are associated with the outcome
in oligometastatic patients [3,6,7]. In the trial by
Gomez et al. [15,23], only treatment type (LRT versus
no LRT) and presence of driver mutations were asso-
ciated with improved PFS. Other patient-related fac-
tors could not be identified, but the number of included
patients in this trial was small. Iyengar et al. [13] ana-
lysed only prognostic factors for PFS within the LRT
group. Hopefully the Stereotactic Ablative Radio-
therapy for Oligometastatic Non-Small Cell Lung
Cancer (SARON) trial (NCT02417662) will provide
some of these answers because patients are stratified as
per mediastinal lymph node status (N0-1 versus N2-3),
histology (adenocarcinoma versus non-
adenocarcinoma), brain metastases (present versus
absent) and the number of oligometastatic sites (1
versus 2 versus 3) [27]. Other interesting factors such as
(metabolic) volume of disease, radiomics features,
molecular signatures (e.g. microRNA’s) and use of
circulating tumour DNA to predict benefit of LRT in
patients with oligometastatic NSCLC should be eval-
uated in future trials [9,28e35]. In addition, it should
be evaluated whether the same predictive factors exist
in patients treated with immunotherapy, as this will
also be more incorporated in the treatment of patients
with oligometastatic NSCLC.5. Conclusion
In this case-based survey, oligometastatic NSCLC defi-
nition in daily practice was conservative. The number of
metastases and organs involved, extent of locoregional
disease and the possibility for radical treatment seem to
be components of the daily practice oligometastatic
definition. Efforts such as by the EORTC oligometa-
static definition consensus group should be made to
provide a uniform definition. This definition should be
tested in future trials and in the OligoCare project.
Furthermore, predictive factors for benefit of LRT
should prospectively be evaluated.Conflict of interest statement
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